Kudo, Mizuki
Ayabe, Naoko
Takeshima, Masahiro
Ogasawara, Masaya
Itoh, Yu
Yoshizawa, Kazuhisa
Kitamura, Shingo
Mishima, Kazuo
Funding for this research was provided by:
National Center of Neurology and Psychiatry (5-1)
Ministry of Health, Labour and Welfare (21GC0801)
Japan Agency for Medical Research and Development (JP21dk0307103KM)
Article History
Received: 12 January 2024
Accepted: 7 June 2024
First Online: 18 June 2024
Competing interests
: MK has received speaker’s honoraria from Meiji Seika Pharma Co., Ltd.; and Otsuka Pharmaceutical outside the submitted work. NA has received speaker’s honoraria from MSD outside the submitted work. NA has also received research grants from the Japanese JSPS KAKENHI (22K03095) outside the submitted work. MT has received speaker’s honoraria from Takeda Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical; Daiichi Sankyo Company; Sumitomo Pharma Co., Ltd.; Meiji Seika Pharma; Viatris Pharmaceuticals Japan; MSD; Eisai Co., Ltd.; and Yoshitomi Pharmaceutical outside the submitted work. MT has also received research grants from the Japanese Ministry of Health, Labour and Welfare (R3-21GC1016) outside the submitted work. MO declares no conflict of interest. YI has received speaker’s honoraria from Sumitomo Pharma Co., Ltd. outside the submitted work. KY has received speaker’s honoraria from Meiji Seika Pharma Co., Ltd.; Eisai Co., Ltd.; Yoshitomi Pharmaceutical; and Kowa Co., Ltd. outside the submitted work. SK has received research grants from the Japanese JSPS KAKENHI (21K06368); Mitsui Fudosan Co., Ltd. outside the submitted work. KM has received speaker’s honoraria from Eisai Co., Ltd.; Nobelpharma Co., Ltd.; MSD; and Takeda Pharmaceutical Co., Ltd. outside the submitted work. KM has also received research grants from AMED (23dk0307103s0203, 24dk0307132s0401); the Japanese Ministry of Education, Science, and Technology no. 22H02992; Eisai Co., Ltd.; Sumitomo Pharma Co., Ltd.; and Takeda Pharmaceutical Co., Ltd. outside the submitted work.